The Association Between Inflammatory and Oxidative Stress Biomarkers and Plasma Metabolites in a Longitudinal Study of Healthy Male Welders

Shangzhi Gao 1
Corbin Quick 2
Marta Guasch-Ferre 3
Zhu Zhuo 2
John M Hutchinson 2
Li Su 1
Frank Hu 3
Xihong Lin 2
David Christiani 1, 4

1Environmental Health, Harvard University T H Chan School of Public Health, Boston, MA, USA; 2Biostatistics, Harvard University T H Chan School of Public Health, Boston, MA, USA; 3Nutrition, Harvard University T H Chan School of Public Health, Boston, MA, USA; 4Pulmonary and Critical Care Division, Department of Medicine, MA General Hospital, Boston, Massachusetts, USA

Introduction: Human metabolism and inflammation are closely related modulators of homeostasis and immunity. Metabolic profiling is a useful tool to understand the association between metabolism and inflammation at a systemic level.

Objective: To investigate the longitudinal associations between the concentration of plasma metabolites and biomarkers related to inflammation and oxidative stress.

Methods: We conducted a repeated cross-sectional analysis consisting of 8 short-term panels that included 88 healthy adult male welders in Massachusetts, USA. In each panel, we collected 1–6 repeated measurements of blood and urine. We used a human vascular injury panel assay and custom cytokine/chemokine assay to quantify inflammatory biomarker plasma levels, liquid chromatography-mass spectrometry to quantify the concentrations of 665 plasma metabolites, and a competitive enzyme-linked immunoassay to quantify urinary 8-OHdG and 8-isoprostane levels. We used linear mixed effects models to estimate the longitudinal association between each inflammatory and oxidative stress biomarker and each metabolite.

Results: At a 5% FDR threshold, we detected ≥1 metabolite association for 8 unique inflammatory and oxidative stress biomarkers: urinary 8-isoprostane, plasma C-reactive protein (CRP), serum amyloid A (SAA), intercellular adhesion molecule 1, circulating vascular cell adhesion molecule-1, interleukin 8 (IL-8), interleukin 10 (IL-10) and vascular endothelial growth factor. Specifically, 3 metabolites in the androgenic steroids pathway were negatively associated with SAA; 3 dihydro-sphingomyelins metabolites were positively associated with 1 or more of CRP, SAA, IL-8 and IL-10; 4 metabolites in acyl choline metabolism pathways were negatively associated with IL-8; 7 lysophospholipid metabolites were negatively associated with 1 or more of CRP, SAA and IL-8; 4 sphingomyelins were positively associated with CRP and/or SAA; and 10 metabolites in the xanthine pathway were positively associated with urinary 8-isoprostane.

Conclusion: We found that metabolites in phospholipid groups had strong associations with multiple inflammatory biomarkers, especially CRP, SAA and IL-8. The mechanism of these associations warrants further investigation.

Keywords: metabolism, inflammation, phospholipids, metals, particulates, metabolomics, occupational health

Introduction
Inflammation is a central component of the innate immune response. Acute inflammation is a protective mechanism triggered by irritants, infection, and injury, and initiated by the release of pro-inflammatory cytokines. 1 Following inflammation,
immune cells release signaling biochemicals, such as the major acute phase proteins C-reactive protein (CRP) and Serum Amyloid A (SAA), which mediate a series of biochemical events in response to cell and tissue damage. Blood flow increases, and leukocytes are recruited to eliminate foreign substances, clear necrotic cells, and initiate tissue repair.

Inflammation plays an important role in many common diseases. Conditions such as obesity cause persistent immune activation, causing chronic inflammation in which these biochemical cascades reoccur over a prolonged period of time. Chronic inflammation also plays a role in the etiology of many diseases, including cardiovascular diseases (CVD), diabetes mellitus (DM), and arthritis.

The biochemical pathways of inflammation and metabolism are interconnected in the development of CVD and DM. Numerious studies have investigated the association between inflammatory biomarkers, especially CRP, and the risk of CVD and metabolic syndromes. Lipid metabolism is especially important in maintaining the health of the cardiovascular system. A diet intervention study found that inflammation was an effect modifier for reduced-fat low-cholesterol diet intervention to control CVD.

After the diet intervention, participants with increased CRP level showed less total and low-density lipoproteins (LDL) cholesterol reduction and a greater increase in triglycerides, compared to participants with lower CRP level. This study suggested a mechanism by which inflammation might increase CVD risk by affecting lipid metabolism. Particularly, inflammation and lipid signaling interact with each other and play important roles in the etiology of insulin resistance, for example, saturated fatty acids (SFA) promote chronic tissue inflammation which can cause insulin resistance.

Understanding the relationship between inflammation and metabolism is important to improve knowledge of the risk of CVD and metabolic syndrome. Each of the above epidemiological studies examined a few particular pathways. However, more metabolic pathways may also interact with inflammation simultaneously. Given this complexity, metabolomics techniques could be useful tools to study this dynamic. To our knowledge, no previous studies have examined the longitudinal associations between inflammation and metabolomics.

In this study, we analyzed the longitudinal association between a panel of inflammatory and oxidative stress biomarkers and the plasma metabolome. We aimed to expand our understanding of the relationship between inflammation and metabolism from a broader view at the molecular level.

Method

Study Population

The participants are members of the International Brotherhood of Boilermakers, Local 29, whose job duties are welding and cutting mild steel, and repairing commercial boilers. The union provides welding technique training programs in summers and winters, in which we invited instructors and apprentices to participate this study. The detailed sample collection timeline is described in Table 1.

During the winters and summers of 2010–2012, we conducted 8 short panel studies in the welding school. In 7 of the 8 study periods, we collected 3–4 repeated measurements of both plasma and urine from each participant. Some participants joined multiple times in different panels.

All study procedures were approved by the Institutional Review Board of Harvard T.H. Chan School of Public Health.

Measurements of Biomarkers

The measurement method of vascular injury biomarkers and pro-inflammatory cytokines was published previously. Briefly, EDTA-treated plasma was obtained from participants by venipuncture of the median cubital vein of the antecubital fossa using BD vacutainer, and centrifuging at 1200 RPM for 12 minutes. The aliquots were stored in cryogenic tubes at −80°C before the assay. Plasma concentrations of CRP, SAA, soluble intercellular adhesion molecule 1 (sICAM-1), circulating vascular cell adhesion molecule-1 (sVCAM-1) were determined using the MULTI-SPOT® 96-well Human Vascular Injury Panel II assay (Meso Scale Discovery, Rockville MD). Plasma concentrations of interleukin-1β (IL-1β), IL-2, IL-6, IL-8, IL-10, tumor necrosis factor alpha (TNFα), and vascular endothelial growth factor (VEGF) were determined using the 7-plex MULTI-ARRAY® 96-well custom cytokine/chemokine assay. The average within-plate coefficients of variation (the ratio of the standard deviation to the mean) ranged from 7.6% to 10.9% for different assays. The average between-plate CVs ranged from 12.3% to 17.4% for different assays.
U-8-OHdG and u-8-isoprostane levels were both determined using competitive enzyme-linked immunoassay method performed by Genox Corporation (Baltimore, MD), as published previously.\(^1^7\)

**Profiling of Metabolites**

Metabolite profiling procedures were described previously.\(^1^8\) EDTA-plasma aliquots were taken from the same samples used for inflammatory biomarker measurements. Morning blood samples were taken after fasting, prior to a provided breakfast, and afternoon blood samples were drawn after the participants performed 5 to 6 hours of welding without lunch.

Proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. Samples were stored in liquid nitrogen before analysis. At the time of sample processing, each sample was aliquoted into 4 fractions for different analytical techniques and each method differentiates and quantifies some metabolites.

Sample extracts were dried then reconstituted in proper solvents for each of the four methods. We prepared each reconstitution solvent based on standards at fixed concentrations to ensure injection and chromatographic consistency.

All methods utilized Waters ACQUITY ultra-performance liquid chromatography (UPLC) method and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source, as well as Orbitrap mass analyzer operated at 35,000 mass resolution. One aliquot was analyzed under acidic positive ion conditions using electrospray ionization (ESI) method, chromatographically optimized for more hydrophilic compounds. In this method, the extract was gradient eluted from a C18 column (Waters UPLC BEH C18-2.1x100 mm, 1.7 µm) using water and methanol that contain 0.05% perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). Another aliquot was also analyzed using acidic positive ion mode ESI, but chromatographically optimized for more hydrophobic compounds. In this method, the extract was gradient eluted using the same method above and was operated at an overall higher organic content. The third aliquot was analyzed under basic negative ion optimized conditions using ESI, eluted from a separate dedicated C18 column by methanol and water with 6.5mM Ammonium.

---

**Table 1 The Timeline and the Number of Blood Samples Collected in Each Study Panel**

| Sampling Period* | Panel | N | Participants | Samples | Non-Welding Day | Welding Day | Non-Welding Day |
|------------------|-------|---|--------------|---------|-----------------|-------------|-----------------|
|                  |       |   | The Previous Morning | The Previous Afternoon | Morning (Pre-Shift) | Afternoon (Post-Shift) | The Next Morning | The Morning a Few Days Later |
| Jan. 2010 - Feb. 2010 | 1     | 31 | 94           | 33 samples | 31 samples | 30 samples |
| Jun. 2010 - Jul. 2010 | 2     | 25 | 80           | 24 samples | 24 samples | 23 samples | 9 samples |
| Jun. 2010 - Jul. 2010 | 3     | 18 | 56           | 4 samples | 19 samples | 17 samples | 16 samples |
| Sept. 2010-Oct. 2010 | 4     | 23 | 37           | 22 samples | 15 samples |
| Jan. 2011 - Feb. 2011 | 5     | 23 | 92           | 15 samples | 12 samples | 22 samples | 22 samples | 4 samples | 17 samples |
| Jun. 2011 | 6     | 26 | 84           | 17 samples | 15 samples | 26 samples | 26 samples |
| Feb. 2012 | 7     | 9  | 9            | 9 samples |
| Jun. 2012 | 8     | 23 | 77           | 21 samples | 19 samples | 19 samples | 18 samples |

Notes: *A total of 88 welders participated in the study. A total of 529 observations have both inflammatory biomarkers and metabolite levels available. The inflammatory biomarkers were analyzed from blood and urine samples, but this form only shows numbers of blood samples. Overall, each participant provided 1–18 repeated measurements, with a median of 4 and an average of 6. Within each study panel, each participant provided 1–6 samples, with a median of 3 and mean of 3 samples. \(^a\)
Bicarbonate at pH 8. The last aliquot was analyzed via negative ESI following elution from a HILIC column (Waters UPLC BEH Amide 2.1×150 mm, 1.7 µm) using a gradient consisting of water and acetonitrile with 10mM Ammonium Formate, pH 10.8. We used MS and data-dependent MSn scans with dynamic exclusion for quantification. The scan range for the above methods covered 70–1000 m/z.

A total of 665 biochemical metabolites were analyzed from each plasma sample, including amino acid, carbohydrates, cofactor/vitamins, lipids, nucleotides, alky characterized molecules, peptides, and xenobiotic metabolites. Further information of these metabolites is given in supplementary materials (Supplementary material – a list of metabolites).

Before the analysis of metabolites, internal standards were added to each sample for quality control purposes. Instrument variability was 4%, determined by calculating the median relative standard deviation (RSD) for the internal standards that were added to each sample before injection into the mass spectrometers. Additionally, a reference sample pooled from a few plasma samples served as the lowest detectable concentration of each compound. Missing values due to low concentration were imputed by the lowest detectable concentration of each compound. Concentrations were the median-scaled for each sample. Measurements for each compound were log-transformed and mean-centered across samples statistical analysis.

**Covariates**

The covariates of the analysis include self-reported age, race, current smoking status (current smoker or not); body mass index (BMI) measured by research staff; the time of sample collection (AM/PM), and whether it is on welding day or not, and study panel (nominal). If participants attended more than one panel, the measurements were taken in each panel. There was no missing value on these covariates.

**Statistical Analysis**

We used linear mixed-effect models (LMMs) to evaluate the association between each biomarker and each metabolite to account for unbalanced repeated measurements. Because many biomarker concentration measurements had skewed and heavily tailed distributions, we applied rank-normal transformations to each biomarker prior to analysis to improve robustness.

For each biomarker and each metabolite, we fit an LMM to model rank-normal transformed biomarker measurement (the response variable) as a function of metabolite concentration and control covariates (listed in the previous paragraph). We compared 2 model specifications for random effects: (1) including a participant-specific random intercept, and (2) including both a participant-specific and participant-and-study-panel-specific random intercept. Here study panel refers to a period of 1–2 days wherein each participant provided 1–6 samples (median 3). For example, one participant joined two study panels in winter 2010 and summer 2012 and provided 3 samples and 4 samples, respectively. Under the first model, there is a single participant-specific intercept across 7 samples, whereas the second model further includes participant-specific intercepts for the first 3 (winter 2010) and second 4 (summer 2012) samples. All models were conducted on a complete case basis.

Formally, we assumed the model

\[ y_{ijk} = m_{ijk} + x_{ijk}^T \alpha + b_i + b_j + \epsilon_{ijk} \]

where \( y_{ijk} \) denotes the rank-normal transformed biomarker measurement for participant \( i \) at study panel \( j \) and sample number \( k \), \( m_{ijk} \) denotes metabolite measurement, and \( x_{ijk} \) denotes the vector covariates (age, BMI, race, smoking status, weld day/non-weld day, AM/PM, and study panel). The random intercepts are independently distributed \( b_i \sim N(0, \tau^2) \) and \( b_j \sim N(0, \gamma^2) \), and the residuals \( \epsilon_{ijk} \sim N(0, \sigma^2) \), where \( N(\cdot) \) denotes the normal distribution. In model 1, we estimate \( \tau^2 \) and fix \( \gamma^2 = 0 \), while in model 2, we estimate both \( \tau^2 \) and \( \gamma^2 \).

The linear mixed-effect model was conducted using the lme4 R package.\(^{19}\)

Next, we used the likelihood ratio test to compare the full model (estimating both \( \tau^2 \) and \( \gamma^2 \) with the nested model with only a per-participant random effect (fixing). In nested model comparisons, the full model fit significantly better than the single-intercept model (p<0.05) for 9/13 biomarkers; we therefore used the full model in subsequent analysis. The model comparison was performed using the varTestnlme R package.\(^{20}\)

Then, we used likelihood ratio tests to evaluate whether we should include panel, AM/PM, and welding day/non-welding day in the covariate list. We finalized the full model and applied it for each biomarker and each metabolite with the restricted maximum
likelihood method, and used the false discovery rate (FDR) method for multiple comparisons.21

The metabolites with at least one association at the significance level of <0.1 were selected for visualization by feature-expression heat map using the corrplot and pheatmap R package.22,23 In this plot, the metabolites and biomarkers were reordered using the hierarchical clustering method.24

Furthermore, we selected participants who provided more than 10 biological samples. Additional analysis of longitudinal change of metabolites/biomarkers was performed using mixed models. The model specification and results are provided in Supplementary Table 2 and 3. Scatter plots of inflammatory biomarker and metabolite profiles over days of follow-up are shown in Supplementary Figure 1–31.

Results
The participants’ characteristics are shown in Table 2. The majority of the participants were Caucasians. The average BMI was 29.5%, and 78% of participants had BMI >25. Only 6% of the participants participated reported ever diagnosed with asthma and diabetes, respectively. According to published data, the average breathing-zone PM$_{2.5}$ level over a welding shift was 421 μg/m$^3$, with a standard deviation (SD) of 360 μg/m$^3$, the average breathing-zone PM$_{2.5}$ level in the classroom area was 120 μg/m$^3$, with an SD of 60 μg/m$^3$. The methods of breathing-zone PM$_{2.5}$ measurements were described elsewhere.18 We had a total of 529 plasma samples from 88 participants. Each participant provided 1–18 repeated measurements, with a median of 4 and an average of 6 samples. During each study panel, each participant provided 1–4 samples, with a median of 3 and an average of 3 samples.

The profile of inflammatory and oxidative stress biomarkers are shown in Supplementary Table 1. U-8-isoprostan and U-8-OHdG were measured only once on panel 1, thus had greater number of missing observations. Other missing values can be considered missing at random. The biomarkers that we analyzed were correlated. The longitudinal association between each two inflammatory biomarkers is shown in Figure 1. U-8-isoprostan and U-8-OHdG are associated. The level of CRA, SAA, sICAM-1, sICAM-1 are highly associated with each other, and they are all associated with IL-6.

Among 665 metabolites, seventeen metabolites were associated with U-8-isoprostan; twenty-one metabolites were associated with CRP; twenty-two metabolites were associated with SAA; two metabolites were associated with

| Characteristics       | Mean or N | SD or % |
|-----------------------|-----------|---------|
| Age (years)           | 42.9      | 13.2    |
| BMI (kg/m$^2$)        | 29.5      | 6.5     |
| Smoking status        |           |         |
| Non-current-smoker    | 54        | 62%     |
| Current smoker        | 33        | 38%     |
| Gender                |           |         |
| Male                  | 88        | 100%    |
| Race                  |           |         |
| Caucasian             | 76        | 87%     |
| African American      | 6         | 7%      |
| Asian                 | 3         | 4%      |
| Other                 | 2         | 2%      |
| Diabetes (ever)       |           |         |
| No                    | 80        | 94%     |
| Yes                   | 6         | 6%      |
| Asthma (ever)         |           |         |
| No                    | 79        | 94%     |
| Yes                   | 5         | 6%      |

Figure 1 The association between inflammatory biomarkers. This is an association matrix between each two inflammatory biomarkers. The association was analyzed using the mixed-effect model taking repeated measurements into consideration. All biomarkers were rank-normal transformed. The color and color intensity shows the direction (red: positive, blue: negative) and effect size, respectively. The star marks represent the false discovery rate (FDR) adjusted statistical significance (*FDR P-value < 0.1; **FDR p-value < 0.05).
siCAM-1; one metabolite was associated with sVCAM-1; eighteen metabolites were associated with IL-8; eleven metabolites were associated with IL-10 and seven metabolites were associated with VEGF (Tables 3 and 4). The below associations we report are all at the significance level of <0.05 after FDR adjustment, unless specified.

Seven lipid metabolites were positively associated with U-8-isoprostane (0.22 < β < 0.32), including N-palmitoyl-sphinganine (d18:0/16:0) (dihydroceramide metabolism), two dicarboxylate metabolites, two monohydroxy fatty acid metabolites, 1-oleoyl-GPE (18:1) (lysophospholipid), and 1-steinaroyl-2-oleoyl-GPE (18:0/18:1) (phosphatidylinositol, or PE). Ten xanthine metabolites were positively associated with U-8-isoprostane (0.12 < β < 0.19).

CRP and SAA had similar association profiles, as shown in Figure 2. The color code represents the direction and the effect size, while the number of stars shows the significance level of <0.05 (**) and <0.1 (*), respectively. CRP and SAA were negatively associated with 7 (−0.57 < β < −0.25) and 5 (−0.71 < β < −0.34) lysophospholipid metabolites, respectively. CRP and SAA were positively associated with 2 (β = 0.22 and 0.32) and 3 (0.31 < β < 0.44) dihydro sphingomyelins metabolites, respectively, as well as 4 (0.37 < β < 0.64) and 2 (β = 0.45 and 0.60) sphingomyelins, respectively. CRP was negatively associated with 3 phosphatidylcholine (PC) (−0.23 < β < −0.43) and 1 phosphatidylinositol (PI) (β = −0.23) metabolites. SAA was negatively associated with 3 (−0.29 < β < −0.23) androgenic steroid metabolites.

Plasma siCAM-1 was positively associated with alpha-hydroxyisocaproate and methylmalonate (β = 0.28 and 0.26), and plasma sVCAM-1 was positively associated with pyrogallamine (β = 0.33).

IL-8 and VEGF has several associated metabolites in common, including arachidonoylcholine (β = −0.12 vs β = −0.02), palmitoylcholine (β = −0.14 vs β < 0, p < 0.1), 3-phosphoglycerate (β = 0.15 vs β = 0.12), and thioproline (β = 0.52 vs β > 0, p < 0.1). IL-8 was also associated with dihydro sulfoglycines (β = 0.43 and 0.64), lysophospholipids (β = −0.11 and −0.18), and fatty acids (−0.22 < β < −0.09).

Plasma VEGF was also positively associated with metabolites in purine metabolism. IL-10 was found associated with amino acids, peptide, and several lipid metabolites.

Furthermore, from the additional analysis on participants who provided more than 10 biological samples, we found 18 metabolites that changed over time (p<0.0001, Supplementary Table 2, Supplementary Figure 1–18). Five inflammatory biomarkers of these participants changed over time (p<0.05, Supplementary Table 3, Supplementary Figure 19–31).

Discussion
In this study, we found plasma metabolites that are longitudinally associated with urinary oxidative stress biomarker U-8-isoprostane and plasma inflammatory biomarkers including CRP, SAA, siCAM-1, sVCAM-1, IL-8, IL-10 and VEGF. Phospholipids, including dihydrosphingomyelins, sphingomyelins, lysophospholipids, PC and PI had stronger associations with inflammatory and oxidative biomarkers. In each of above pathways, we found multiple metabolites that were associated with one or more inflammatory and/or oxidative stress biomarkers.

We conducted this study in active workers, who tend to be healthier and more resilient than community populations. No other exclusions were applied in the workers who were willing to participate in the study.

Few studies have evaluated the inflammatory and metabolic profile of active workers. In the same cohort study, our group previously examined the metabolic change and the association between inflammatory biomarker and telomere length. An animal study analyzed the spatial distribution and abundance changes of lipid species in Sprague Dawley rat liver maintained on a high-fat diet combined with welding fume inhalation. This study showed that the combined effects of welding fume inhalation and a high-fat diet significantly altered the hepatic lipidome and researchers found higher abundance of ceramide-1-phosphate in the regular diet welding fume-exposed group which has been shown to regulate the eicosanoid pathway involved in pro-inflammatory response. Thus, our study is the first study focused on the longitudinal association between metabolic profile and inflammatory biomarkers in a working population. The knowledge generated from this study can be generalized to broader active working population. Previous studies elucidated several mechanisms by which lipid species act positively and negatively in regulating inflammatory responses. For example, eicosanoids are signaling molecules derived by the oxidation of arachidonic acid or other polyunsaturated fatty acids (PUFAs) similar to arachidonic acid, and they are bioactive lipid mediators that promote inflammation via innate immunity. SFA are pro-inflammatory lipid compounds that mediate the activation
| Biomarker | Metabolite | Super Pathway                  | Sub Pathway       | Effect Size | FDR p-value |
|-----------|------------|--------------------------------|------------------|-------------|-------------|
| U-8-isoprostane, pg/mg creatinine | N-palmitoyl-sphinganine (d18:0/16:0) | Lipid             | Dihydroceramides | 0.25        | 0.04        |
|          | Azelate (C9-DC) | Lipid             | Fatty Acid, Dicarboxylate | 0.22        | <0.01       |
|          | Docosadiolate (C22-DC) | Lipid             | Fatty Acid, Dicarboxylate | 0.22        | <0.01       |
|          | 2-hydroxydecanoate | Lipid             | Fatty Acid, Monohydroxy | 0.26        | 0.02        |
|          | 2-hydroxyoctanoate | Lipid             | Fatty Acid, Monohydroxy | 0.22        | <0.01       |
|          | 1-oleoyl-GPE (18:1) | Lipid             | Lysophospholipid   | 0.32        | <0.01       |
|          | 1-stearoyl-2-oleoyl-GPE (18:0/18:1) | Lipid             | Phosphatidylethanolamine (PE) | 0.16        | 0.03        |
|          | 1,7-dimethylurate | Xenobiotics        | Xanthine Metabolism | 0.16        | <0.01       |
|          | 1-methylurate | Xenobiotics        | Xanthine Metabolism | 0.12        | 0.02        |
|          | 1-methylxanthine | Xenobiotics        | Xanthine Metabolism | 0.12        | 0.01        |
|          | 3-methylxanthine | Xenobiotics        | Xanthine Metabolism | 0.16        | <0.01       |
|          | 5-acetylamino-6-amino-3-methyluracil | Xenobiotics        | Xanthine Metabolism | 0.19        | <0.01       |
|          | 5-acetylamino-6-formylamino-3-methyluracil | Xenobiotics        | Xanthine Metabolism | 0.12        | <0.01       |
|          | 7-methylxanthine | Xenobiotics        | Xanthine Metabolism | 0.14        | <0.01       |
|          | Paraxanthine | Xenobiotics        | Xanthine Metabolism | 0.14        | <0.01       |
|          | Theobromine | Xenobiotics        | Xanthine Metabolism | 0.14        | <0.01       |
|          | Theophylline | Xenobiotics        | Xanthine Metabolism | 0.18        | <0.01       |
|          | Plasma CRP , ng/mL | Retinol (Vitamin A) | Cofactors and Vitamins | -       | 0.59        |
|          | Androstenediol (3beta,17beta) monosulfate (2) | Lipid             | Androgenic Steroids | -       | <0.01       |
|          | Sphingomyelin (d18:0/18:0, d19:0/17:0)* | Lipid             | Dihydrosphingomyelins | 0.32        | <0.01       |
|          | Sphingomyelin (d18:0/20:0, d16:0/22:0)* | Lipid             | Dihydrosphingomyelins | 0.22        | 0.01        |
|          | Methylmalonate (MMA) | Lipid             | Fatty Acid Metabolism (also BCAA Metabolism) | 0.19        | <0.01       |
|          | 1-linolenoyl-GPC (18:3)* | Lipid             | Lysophospholipid   | -       | <0.01       |
|          | 1-oleoyl-GPC (18:1) | Lipid             | Lysophospholipid   | -       | <0.01       |
|          | 1-palmitoleoyl-GPC* (16:1)* | Lipid             | Lysophospholipid   | -       | <0.01       |
|          | 1-palmitoyl-GPC (16:0) | Lipid             | Lysophospholipid   | -       | <0.01       |
|          | 1-palmitoyl-GPE (16:0) | Lipid             | Lysophospholipid   | -       | <0.01       |
|          | 1-stearoyl-GPC (18:0) | Lipid             | Lysophospholipid   | -       | <0.01       |
|          | 1-stearoyl-GPE (18:0) | Lipid             | Lysophospholipid   | -       | <0.01       |
|          | 1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6)* | Lipid             | Phosphatidylcholine (PC) | -       | 0.01        |
|          | 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)* | Lipid             | Phosphatidylcholine (PC) | -       | 0.01        |
|          | 1-stearoyl-2-oleoyl-GPC (18:0/18:1) | Lipid             | Phosphatidylcholine (PC) | -       | <0.01       |
|          | 1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)* | Lipid             | Phosphatidylinositol (PI) | -       | 0.01        |
|          | 1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* | Lipid             | Plasmalogen       | -       | 0.01        |
|          | Sphingomyelin (d18:1/18:1, d18:2/18:0) | Lipid             | Sphingomyelins    | 0.64        | 0.01        |
|          | Sphingomyelin (d18:1/20:1, d18:2/20:0)* | Lipid             | Sphingomyelins    | 0.54        | <0.01       |
|          | Sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0)* | Lipid             | Sphingomyelins    | 0.37        | <0.01       |
|          | Stearoyl sphingomyelin (d18:1/18:0) | Lipid             | Sphingomyelins    | 0.38        | <0.01       |

(Continued)
Table 3 (Continued).

| Biomarker                  | Metabolite                     | Super Pathway        | Sub Pathway               | Effect Size | FDR p-value |
|----------------------------|--------------------------------|----------------------|---------------------------|-------------|-------------|
| Plasma SAA, ng/mL          | Hydantoin-5-propionate         | Amino Acid           | Histidine Metabolism      | 0.11        | 0.02        |
|                            | Arabitol/xylitol               |                      | Carbohydrate              |             |             |
|                            | Retinol (Vitamin A)            |                      | Vitamin A Metabolism      | -0.66       | <0.01       |
|                            | Salpha-androstan-3beta,17beta-diol disulfate | Lipid               | Androgenic Steroids       | -0.23       | <0.01       |
|                            | Androstenediol (3beta,17beta) disulfate (1) | Lipid               | Androgenic Steroids       | -0.28       | <0.01       |
|                            | Androstenediol (3beta,17beta) monosulfate (2) | Lipid               | Androgenic Steroids       | -0.29       | <0.01       |
|                            | Myristoyl dithyrosphingomyelin (d18:0/14:0)* | Lipid               | Dihyrosphingomyelins      | 0.44        | 0.01        |
|                            | Sphingomyelin (d18:0/18:0, d19:0/17:0)* | Lipid               | Dihyrosphingomyelins      | 0.44        | <0.01       |
|                            | Sphingomyelin (d18:0/20:0, d16:0/22:0)* | Lipid               | Dihyrosphingomyelins      | 0.31        | <0.01       |
|                            | Arachidonyl carnitine (C20:4)  | Lipid               | Fatty Acid Metabolism     | -0.21       | 0.01        |
|                            | Methylmalonate (MMA)           | Lipid               | Fatty Acid Metabolism     | 0.33        | <0.01       |
|                            | 1-oleoyl-GPC (18:1)            | Lipid               | Lysosphospholipid         | -0.39       | 0.04        |
|                            | 1-palmitoleoyl-GPC* (16:1)*    | Lipid               | Lysosphospholipid         | -0.39       | <0.01       |
|                            | 1-palmitoyl-GPC (16:0)         | Lipid               | Lysosphospholipid         | -0.71       | <0.01       |
|                            | 1-shearoyl-GPC (18:0)          | Lipid               | Lysosphospholipid         | -0.50       | 0.01        |
|                            | 1-shearoyl-GPE (18:0)          | Lipid               | Lysosphospholipid         | -0.34       | 0.05        |
|                            | 1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)* | Lipid       | Phosphatidylinositol (PI) | -0.34       | <0.01       |
|                            | 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)* | Lipid       | Phosholipid               | -0.58       | <0.01       |
|                            | Sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0)* | Lipid       | Sphingomyelins            | 0.45        | <0.01       |
|                            | Stearoyl sphingomyelin (d18:1/18:0) | Lipid       | Sphingomyelins            | 0.60        | <0.01       |
|                            | Gabapentin                     | Lipid               | Drug - Neurological       | 0.41        | <0.01       |
|                            | 3-hydroxycotinine glucuronide  | Lipid               | Tobacco Metabolitc         | -0.20       | <0.01       |
| Plasma sICAM-1, ng/mL      | Alpha-hydroxyisocaproate       | Amino Acid           | Leucine, Isoleucine and Valine Metabolism | 0.28 | 0.01 |
|                            | Methylmalonate (MMA)           | Lipid               | Fatty Acid Metabolism     | 0.26        | <0.01       |
| Plasma sVCAM-1, ng/mL      | Pyroglutamine*                 | Amino Acid           | Glutamate Metabolism      | 0.33        | <0.01       |
| Metabolite Description | Metabolite Type | Pathway | Plasma, pg/mL | FDR (p-value) |
|------------------------|----------------|---------|---------------|--------------|
| Plasma IL-8, pg/mL     |                |         | 0.18          | <0.01        |
| Sarcosine              | Amino Acid     | Glycine, Serine and Threonine Metabolism | 0.15 | <0.01 |
| Amino Acid             |               |         | -0.14         | <0.01        |
| Glycine                |               |         | -0.43         | <0.01        |
| Serine                 |               |         | -0.44         | <0.01        |
| Threonine              |               |         | -0.12         | <0.01        |
| Glycolysis, Gluconeogenesis, and Pyruvate Metabolism | 3-phosphoglycerate | Carbohydrate | 0.10 | 0.03 |
| Nicotinate and Nicotinamide Metabolism | Quinolinate | Cofactors and Vitamins | -0.14 | 0.05 |
| Primidine Metabolism, Oxazole containing | 1-palmitoyl-GPI* | Lipid | 0.11 | 0.03 |
| Lysophospholipid | 1-stearoyl-GPI (18:0) | 0.18 | <0.01 |
| Dihydrosphingomyelins | Myristoyl dihydrosphingomyelin (d18:0/14:0)* | Lipid | 0.43 | <0.01 |
| Myristoyl dihydrosphingomyelin (d18:0/14:0)* | Lipid | 0.64 | <0.01 |
| Palmitoyl dihydrosphingomyelin (d18:0/16:0)* | Lipid | 0.64 | <0.03 |
| Dihydrosphingomyelins | Arachidonoylcarnitine (C20:4) | Lipid | 0.22 | <0.01 |
| Fatty Acid Metabolism (Acyl Carnitine, Polyunsaturated) | Arachidonoylcholine | Lipid | 0.12 | <0.01 |
| Fatty Acid Metabolism (Acyl Choline) | Linoleoylcholine* | Lipid | 0.12 | <0.01 |
| Fatty Acid Metabolism (Acyl Choline) | Oleoylcholine | Lipid | 0.09 | <0.01 |
| Fatty Acid Metabolism (Acyl Choline) | Palmitoylcholine | Lipid | 0.14 | <0.01 |
| Fatty Acid Metabolism (Acyl Choline) | 1-palmitoyl-GPI* (16:0) | Lipid | 0.11 | 0.03 |
| Fatty Acid Metabolism (Acyl Choline) | 1-stearoyl-GPI (18:0) | Lipid | 0.18 | <0.01 |
| Fatty Acid Metabolism (Acyl Choline) | AMP | Nucleotide | 0.28 | 0.01 |
| Purine Metabolism, Adenine containing | Dihydroorotate | Nucleotide | -0.27 | <0.01 |
| Pyrimidine Metabolism, Orotate containing | N-methylpipecolate | Xenobiotics | 0.15 | <0.01 |
| Bacterial/Fungal | EDTA | Chemical | 0.15 | <0.01 |
| Chemical | Thioproline | Chemical | 0.52 | <0.01 |
| Chemical | AMP | Nucleotide | 0.28 | 0.01 |
| Purine Metabolism, Adenine containing | Dihydroorotate | Nucleotide | -0.27 | <0.01 |
| Pyrimidine Metabolism, Orotate containing | N-methylpipecolate | Xenobiotics | 0.15 | <0.01 |
| Bacterial/Fungal | EDTA | Chemical | 0.15 | <0.01 |
| Chemical | Thioproline | Chemical | 0.52 | <0.01 |
| Chemical | AMP | Nucleotide | 0.28 | 0.01 |
| Purine Metabolism, Adenine containing | Dihydroorotate | Nucleotide | -0.27 | <0.01 |
| Pyrimidine Metabolism, Orotate containing | N-methylpipecolate | Xenobiotics | 0.15 | <0.01 |
| Bacterial/Fungal | EDTA | Chemical | 0.15 | <0.01 |
| Chemical | Thioproline | Chemical | 0.52 | <0.01 |
| Chemical | AMP | Nucleotide | 0.28 | 0.01 |
| Purine Metabolism, Adenine containing | Dihydroorotate | Nucleotide | -0.27 | <0.01 |
| Pyrimidine Metabolism, Orotate containing | N-methylpipecolate | Xenobiotics | 0.15 | <0.01 |
| Bacterial/Fungal | EDTA | Chemical | 0.15 | <0.01 |
| Chemical | Thioproline | Chemical | 0.52 | <0.01 |
| Chemical | AMP | Nucleotide | 0.28 | 0.01 |
| Purine Metabolism, Adenine containing | Dihydroorotate | Nucleotide | -0.27 | <0.01 |
| Pyrimidine Metabolism, Orotate containing | N-methylpipecolate | Xenobiotics | 0.15 | <0.01 |
| Bacterial/Fungal | EDTA | Chemical | 0.15 | <0.01 |
| Chemical | Thioproline | Chemical | 0.52 | <0.01 |
| Chemical | AMP | Nucleotide | 0.28 | 0.01 |
| Plasma IL-8, pg/mL     |                |         | -0.14         | <0.01        |
| Plasma VEGF , pg/mL    |                |         | -0.12         | <0.01        |

Notes: The effect size was derived from linear mixed-effect model adjusted for age, race, current smoking status, body mass effect, time of sample collection and whether it is on a welding day or not, as well as adjusted for random intercept effect of each participant and each study panel. The p-value was corrected using false discover rate (FDR) method.

Abbreviations: IL-8, interleukin 8; IL-10, interleukin 10; VEGF, vascular endothelial growth factor; CRP, C-reactive protein; SAA, serum amyloid A; ICAM-1, intercellular adhesion molecule 1; sVCAM-1, circulating vascular cell adhesion molecule 1; BCAA, branched-chain amino acid; sTREM1, soluble triggering receptor expressed on myeloid cells 1; M1-08, immunosuppressive molecule 1; M1-05, immunosuppressive molecule 2; 8-isoprostane, also known as 15F2t-IsoP or 8-iso-PGF2a.
of toll-like receptors and stimulation of IKKβ/NFκB and JNK1/AP1, and then promote inflammation and the release of cytokines. FSA palmitate was found to induce the activation of the NLRP3-ASC inflammasome, promoting caspase-1, IL-1β, and IL-18 production, which also mediates insulin resistance. LDLs promote cholesterol accumulation and inflammatory response in the artery wall, which drives the process of atherosclerosis.

High-density lipoproteins (HDL) and certain unsaturated fatty-acid can be anti-inflammatory, thus beneficial to arterial health. For example, omega-3 fatty acids, such as DHA and EPA, have an anti-inflammatory effect by inhibiting the production of arachidonic acid and other pro-inflammatory eicosanoids, although the molecular mechanism remains unclear. Omega-3 fatty acid was also found to stimulate GPR120 and the production of resolvins and protectins, which is anti-inflammatory.

On the other hand, studies have shown how inflammation alters lipid metabolism at the whole-body level and in different tissues. For example, inflammation triggered
infection by bacteria or viruses may change lipid and lipoprotein metabolism. TNF-α was found to suppress lipoprotein lipase synthesis, which could contribute to hypertriglyceridemia. IL-6 selectively alters skeletal muscle lipid metabolism. Lipopolysaccharides (LPS), TNF-α, and IL-1β are involved in lipolysis in primary adipocytes and adipocyte cell lines.

There are few overlaps between the known mechanisms above and the detailed metabolite-biomarker association in our findings. For example, we have not found significant associations between any examined metabolites and IL-1β, which played important role in above mechanisms. It is possible that our repeated cross-sectional analysis only reflects systemic association, while temporal relationship between the metabolites and inflammatory markers cannot be determined. In this longitudinal setting, we identified multiple metabolites that were associated with U-8-isoprostane, CRP, SAA, sICAM-1, sVCAM-1, IL-8, IL-10, and VEGF. We further examined the literature for insight into possible mechanisms of these associations.

The isoprostane family is prostaglandin-like compounds formed in vivo from the free radical-catalyzed peroxidation of essential fatty acids (primarily arachidonic acid). An imbalance between the production and elimination of reactive oxygen species, including free oxygen radicals, are closely associated with inflammation. Creatinine-adjusted urinary 8-isoprostane is the most commonly used biomarker for oxidative stress in human studies. U-8-isoprostane was found positively associated with xanthine metabolites that are related to caffeine digestion. One study showed that the superoxide-producing enzyme xanthine oxidase may elevate the release of isoprostane in human isolated pulmonary artery smooth muscle cells.

In addition, U-8-isoprostane was associated with several lipids; however, the mechanism is not well understood. Azelate (C9-DC) was found negatively associated with circulating IL-6 in older adults in a cross-sectional study, but not oxidative stress biomarkers.

CRP is an acute phase pro-inflammatory protein made by the liver following the stimulation of IL-6. CRP levels in the blood increase when there is a condition causing inflammation, such as infection, rheumatic, and other inflammatory diseases. It is an important biomarker of acute conditions, as well as of the severity of disease in chronic conditions. Healthy people’s CRP level should be under 3000 ng/dL, and the average CRP level of our measurements was ~4000 ng/dL (median ~2000 ng/dL), indicating that our study results can be generalized to health working men or man with acute or chronic inflammation conditions.

CRP and SAA were both associated with several sphingomyelins (positive) and lysophospholipids (negative) metabolites, while the mechanism was not yet clear. One previous study postulates that lysophospholipids constitute the ligand for CRP in the ischemic myocardium that CRP can bind to phosphatidylcholine vesicles containing lysophosphatidylcholine. Another study suggested that the sphingomyelin-ceramide pathway participates in the induction of CRP and SAA by IL-6 and IL-1β in cell cultural experiments, most likely by transducing the effects of IL-1β.

VEGF is a signaling protein that regulates endothelial cell function and promotes angiogenesis. We found VEGF and IL-8 were both positively associated with the plasma level of 5’ adenosine monophosphate (AMP). Few studies discussed the relationship between AMP and VEGF but many studies demonstrated how AMP-activated protein kinase (AMPK) and VEGF stimulates each other in the process of angiogenesis. For example, cell culture studies showed that AMP-activated protein kinase stimulates VEGF expression and angiogenesis in skeletal muscle. AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. In addition, VEGF stimulates AMPK by a CaMKK-dependent mechanism and stimulation of AMPK activity is required for proliferation in response to either VEGF-A or -B and migration in response to VEGF-A.

IL-8 is a chemokine produced by macrophages and other cell types. Known as a neutrophil chemotactic factor, it has two major functions. First, it induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate toward the site of infection, and stimulates phagocytosis once they have arrived. Second, it promotes angiogenesis, which echoed our finding that it is associated with AMP along with VEGF. IL-8 was found to up-regulates VEGF mRNA and protein levels in endothelial cells by acting on its cognate receptor, CXCR2, and it results in the autocrine activation of VEGF receptor 2.

Among the cytokines, IL-6 is well known for inducing the liver synthesis of CRP and SAA in the acute phase of inflammation. However, we have not found any metabolite significantly associated with IL-6 in this study.

In Figure 1, we observed that IL-1, IL-6, IL-8, IL-10, TNF-α, and VEGF are associated with each other. The
Figure 2 The hierarchical clustered feature-expression heat map of metabolite-inflammatory biomarker associations. Figure 2 is a feature-expression heat map depicting the longitudinal association between plasma metabolite concentration and plasma/urine inflammatory biomarker concentration. Statistical analysis was performed using the linear mixed-effect regression model. In the visualization, the color and color intensity shows the direction (red: positive, blue: negative) and effect size, respectively. The star marks represent the false discovery rate (FDR) adjusted statistical significance (*FDR P-value < 0.1; **FDR p-value < 0.05).
functional relationship may explain the correlation between inflammatory and oxidative stress biomarkers, and the similarity in association profiles, especially between CRP and SAA, as well as between VEGF and IL-8.

This study has several strengths. First, the repeated measurements from participants allowed us to assess the longitudinal association between inflammatory biomarkers and the metabolome, while previous epidemiological studies used cross-sectional designs. Second, large numbers of biomarkers and metabolites of each time point were measured at the same time, which ensures the same stage of metabolism and homeostasis. Third, we used linear mixed effects models to account for the unbalanced repeated measures and within-subject correlations.

There are also limitations of the study. First, many metabolites are functionally interrelated and statistically correlated, making it difficult to disentangle the effects. Second, immune responses may be delayed, and length of delay may vary across different inflammatory biomarkers. Such delays are not captured in the linear mixed model we used to quantify longitudinal associations, and therefore could bias the estimates. Third, because relatively few time points are available for each individual in the study, temporal precedence of changes in metabolites and inflammatory markers is not clear. Fourth, our analysis does not estimate causal effects, as longitudinal associations could be driven by causal effects in either direction or by omitted third variables that affect both metabolomics and inflammations.

In conclusion, in this longitudinal analysis in healthy male workers, we found novel associations between inflammatory and oxidative stress and metabolites including lysosphospholipid, dihydrosphingomyelins, sphingomyelins, PC, PI, xanthine metabolism and fatty acid metabolism pathways. The mechanism underlying these associations should be investigated further to understand the etiology of inflammation-related diseases.

Abbreviations
IL-1β, interleukin 1 beta; IL-2, interleukin 2; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor; CRP, C-reactive protein; SAA, serum amyloid A; ICAM-1, intercellular adhesion molecule 1; sVCAM-1, circulating vascular cell adhesion molecule-1; 8-isoprostane, also known as 15F2t-IsoP or 8-iso-PGF2a; 8-OHdG, 8-Oxo-2′-deoxyguanosine; RP/UPLC-MS, reverse phase ultrahigh performance liquid chromatography-tandem mass spectroscopy.

Code Availability
The code of this study is not available to the public.

Data Sharing Statement
Data of this study are not available in a public open access repository.

Ethics Approval
All study procedures were approved by the institutional review board of the Harvard T H Chan School of Public Health. This study was conducted in accordance with the Declaration of Helsinki.

Consent to Participate
Signed informed consent was obtained from all study participants in each study period.

Acknowledgment
The authors appreciate the cooperation of study participants and the kind support of the International Brotherhood of Boilermakers Union, Local 29 in Quincy, Massachusetts. We thank Tianteng Fan, Jinming Zhang, Jason Wong, Jennifer M Cavallari, Ema Rodrigues and other former team members for their effort building this cohort and collecting data and samples.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding
This study was supported by a grant (5R01ES009860) by National Institute of Environmental Health Sciences. SG and DC were supported by grant (T42OH008416) by National Institute of Occupational Safety and Health, Centers for Disease Control and Prevention, US Department of Health and Human Services.
Disclosure
There was no conflict of interested reported by any of the authors.

References
1. Keyel PA. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine. 2014;69(1):136–145. doi:10.1016/j.cyt.2014.03.007
2. Goldstein IM, Snyderman R, Gallin JI. Inflammation: Basic Principles and Clinical Correlates. Raven Press; 1992.
3. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–1832. doi:10.1038/s41591-019-0675-0
4. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867. doi:10.1038/nature05485
5. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511. doi:10.1161/01.cir.0000052939.59093.45
6. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
7. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182.
8. Ridker PM, Buring JE, Cook NR, Rifai NJC. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2002;106(21):2722–2727. doi:10.1161/01.cir.0000095014.62083.05
9. Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res. 2020;126(11):1549–1564. doi:10.1161/CIRCRESAHA.119.315896
10. Marques-Vidal P, Velho S, Waterworth D, Waeger G, von Känel R, Vollenweider PJE. The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used. Eur J Clin Nutr. 2012;66(4):426–435. doi:10.1038/ejcn.2011.170
11. van den Brink W, van Bilsen J, Salic K, et al. Current and future nutritional strategies to modulate inflammatory dynamics in metabolic disorders. Front Nutr. 2019;6:129.
12. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110(4):380–385. doi:10.1161/01.CIR.0000136581.59584.0E
13. Erlinger TP, Miller lii ER, Charleston J, Appel LJ. Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. Circulation. 2003;108(2):150–154. doi:10.1161/01.CIR.0000080288.30567.86
14. Grundy SM. Inflammation, metabolic syndrome, and diet responsiveness. Am Heart Assoc. 2003;292(23):3000. doi:10.1001/jama.290.23.3000
15. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15(5):635–645. doi:10.1016/j.cmet.2012.04.001
16. Wong JY, De Vivo I, Lin X, Fang SC, Christiani DC. The relationship between inflammatory biomarkers and telomere length in an occupational prospective cohort study. PLoS One. 2014;9(1):e87348. doi:10.1371/journal.pone.0087348
17. Nuernberg AM, Boyce PD, Cavallari JM, Fang SC, Eisen EA, Christiani DC. Urinary 8-iso prostaglandin F2α and 8-OHdG concentrations in boilermakers with welding exposure. J Occup Environ Med. 2008;50(2):182–189. doi:10.1097/JOM.0b013e3181515e6cc
18. Gao S, Zhuo Z, Hutchinson J, Su L, Christiani DC. Metabolomic profiling identifies plasma sphingosine 1-phosphate levels associated with welding exposures. Occup Environ Med. 2020;0emed-2020-106918.
19. Bates D, Sarkar D, Bates MD, Matrix LJR. The lm4e package. Curr Drug Saf. 2007;2(1):74. doi:10.2174/1574888077781668855
20. Baey C, Courmède P, Kuhn E. Asymptotic distribution of likelihood ratio test statistics for variance components in nonlinear mixed effects models. Computational Statistics and Data Analysis. 2019;135:107–122.
21. Benjamini Y, Hoehberg YJ. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B.1995;57(1):289–300.
22. Haarman BCB, Riemersma-van der Lek RF, Nolen WA, Mendes R, Drexhage HA, Burger HJ. Feature-expression heat maps–A new visual method to explore complex associations between two variable sets. Journal of Biomedical Informatics. 2015;53:156–161.
23. Wei T, Simko V, Levy M, Xie Y, Jin Y, Zemla JJS. Package ‘corplot’. Inorg Chem. 2017;56(36):e24. doi:10.1021/acs.inorgchem.7b00995
24. Johnson SC. Hierarchical clustering schemes. Psychometrika. 1967;32(3):241–254. doi:10.1007/BF02289588
25. Boyce GR, Shoeb M, Kodali V, et al. Welding fume inhalation exposure and high-fat diet change lipid homeostasis in rat liver. Toxicol Rep. 2020;7:1350–1355. doi:10.1016/j.toxrep.2020.10.008
26. Dennis EA, Norris PC. Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015;15(8):511–523. doi:10.1038/nri3859
27. Weng H, Gris D, Lei Y, et al. Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12(5):408–415. doi:10.1038/ni.2022
28. Tall AR, Yvan-Charvet LJ. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104–116. doi:10.1038/nri3793
29. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah G, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95(8):764–772. doi:10.1161/01.RES.0000146094.59640.13
30. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):678–698. doi:10.1016/j.cell.2010.07.041
31. Kawakami M, Murase T, Ogawa H, et al. Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipidosis in 3T3-L1 cells. J Biochem. 1987;101(2):331–338. doi:10.1093/oxfordjournals.jbchem.a121917
32. Wolsk E, Mygind H, Grøndahl TS, Pedersen BK, van Hall GJ. Metabolism. IL-6 selectively stimulates fat metabolism in human skeletal muscle. American J Physiol Endocrinol Metab. 2010;299(5):E832–E840. doi:10.1152/ajpendo.00328.2010
33. Ryden M, Dicker A, van Harmelen V, et al. Mapping of early signaling events in tumor necrosis factor-a-mediated lipidosis in human fat cells. J Bio Chem. 2002;277(2):1085–1091. doi:10.1074/jbc.M109498200
34. Milne GL, Yin H, Hardy KD, Davies SS, Roberts LJ. Isoprostane generation and function. Chem Rev. 2011;111(10):5973–5996. doi:10.1021/cr200160h
35. Graille M, Wild P, Sauvain J, Hemmendinger M, Canu IG, Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):678–698. doi:10.1016/j.cell.2010.07.041
36. Ryden M, Dicker A, van Harmelen V, et al. Mapping of early signaling events in tumor necrosis factor-a-mediated lipidosis in human fat cells. J Bio Chem. 2002;277(2):1085–1091. doi:10.1074/jbc.M109498200
37. Lustgarten MS, Fielding RAJ. Metabolites associated with circulating interleukin-6 in older adults. J Gerontol. 2017;72(9):1277–1283. doi:10.1093/gerona/glw039
38. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? *Circulation*. 1999;100(1):96–102. doi:10.1161/01.cir.100.1.96

39. Lozanski G, Berthier F, Kushner IBJ. The sphingomyelin–ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A but not α-Fibrinogen. 1997;328(1):271–275.

40. Fisslthaler B, Fleming IJ. Activation and signaling by the AMP-activated protein kinase in endothelial cells. *Circ Res*. 2009;105(2):114–127. doi:10.1161/CIRCRESAHA.109.201590

41. Li Y, Sun R, Zou J, Ying Y, Luo Z. Dual roles of the AMP-activated protein kinase pathway in angiogenesis. *Cells*. 2019;8(7).

42. Stahmann N, Woods A, Spengler K, et al. Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. *J Biol Chem*. 2010;285(14):10638–10652. doi:10.1074/jbc.M110.108688

43. Ouchi N, Shibata R, Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. *Circ Res*. 2005;96(8):838–846. doi:10.1161/01.RES.0000163633.10240.3b

44. Reihill JA, Ewart MA, Hardie DG, Salt IP. AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. *Biochem Biophys Res Commun*. 2007;354(4):1084–1088. doi:10.1016/j.bbrc.2007.01.110

45. Reihill JA, Ewart M-A, Salt IP. The role of AMP-activated protein kinase in the functional effects of vascular endothelial growth factor-A and -B in human aortic endothelial cells. *Vasc Cell*. 2011;3(1):9. doi:10.1186/2045-824X-3-9

46. Ning Y, Manegold PC, Hong YK, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo colon cancer cell line models. *Int J Cancer*. 2011;128(9):2038–2049. doi:10.1002/ijc.25562

47. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFκB through the CBM (Carma3/Bcl10/Malt1) complex. *J Biol Chem*. 2009;284(10):6038–6042. doi:10.1074/jbc.C800207200

48. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol*. 2014;6(10):a016295. doi:10.1101/cshperspect.a016295

Journal of Inflammation Research

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-inflammation-research-journal